Want to see HK:2269 full AI Analyst Report?

Wuxi Biologics (Cayman) (2269) Price & Analysis

59 Followers

2269 Stock Chart & Stats

HK$50.65

HK$0.80(2.07%)

At close: Jul 29 4:00 PM EDT

HK$50.65

HK$0.80(2.07%)

Day’s Range― - ―

52-Week RangeHK$28.48 - HK$58.00

Previous CloseN/A

Volume23.61M

Average Volume (3M)29.99M

Market Cap

HK$206.04B

Enterprise ValueHK$140.19B

Total Cash (Recent Filing)HK$13.04B

Total Debt (Recent Filing)HK$2.73B

Price to Earnings (P/E)34.7

Beta1.38

Next Earnings

Mar 23, 2027

EPS Estimate

0.85

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)1.21

Shares Outstanding4,116,762,000

10 Day Avg. Volume42,291,798

30 Day Avg. Volume29,994,832

Financial Highlights & Ratios

PEG Ratio0.59

Price to Book (P/B)2.49

Price to Sales (P/S)5.41

P/FCF Ratio42.13

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

HK$58.92

Price Target Upside16.33% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering15

EPS Forecast (FY)1.41

Revenue Forecast (FY)HK$25.66B

Bulls Say, Bears Say

Bulls Say

Healthy ProfitabilityHealthy 2025 gross, EBIT, and net margins indicate the CDMO retains meaningful economics across development and manufacturing services. This profitability provides internal funding for capacity and service investment while giving the business resilience as customer programs progress.

Conservative Balance SheetVery low and improving leverage reduces financial strain and leaves Wuxi Biologics greater flexibility to invest in facilities, technology, and customer programs. A sizeable equity base also supports resilience if biologics development timelines or utilization fluctuate.

Improving Cash GenerationThe return to positive free cash flow and strong year-over-year improvement strengthen the company’s ability to fund operations and investment internally. Better cash generation can support capacity expansion and reduce reliance on external financing as demand develops.

Bears Say

Slowing Revenue GrowthThe sharp deceleration in recent revenue growth suggests that expansion is no longer translating into top-line gains at its earlier pace. Slower customer-project progression or service demand could reduce operating leverage and make future profit growth more dependent on execution.

Weak Cash ConversionAlthough cash flow improved, it remains below reported earnings, meaning accounting profitability is not yet converting fully into deployable cash. This can constrain internally funded investment and indicates that working capital or investment needs may continue to absorb earnings.

Margins Below Prior PeaksMargins remain healthy, but their position below prior peaks indicates some normalization or mix and cost pressure compared with earlier performance. If this persists, it could limit incremental earnings growth even if the company continues expanding revenue.

Wuxi Biologics (Cayman) News

WuXi Biologics price target raised to HK$62 from HK$51.10 at UBS

UBS raised the firm’s price target on WuXi Biologics (WXIBF) to HK$62 from HK$51.10 and keeps a Buy...

2M ago

WuXi Biologics: Upgraded Growth Outlook and Higher DCF-Based Target Price Support Buy Rating

Wuxi Biologics (Cayman), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Jill Wu...

2M ago

WuXi Biologics Schedules Conference Calls to Present 2026 Interim Results

Wuxi Biologics (Cayman) ( ($HK:2269) ) just unveiled an update. WuXi Biologics (Cayman) Inc., a Hong Kong-listed provider...

2M ago

Wuxi Biologics Posts Strong Interim Growth as Integrated Biologics Project Portfolio Expands

Wuxi Biologics (Cayman) ( ($HK:2269) ) has provided an announcement. Wuxi Biologics reported unaudited interim results for the...

2M ago

WuXi Biologics sets August board meeting to approve interim 2026 results

Wuxi Biologics (Cayman) ( ($HK:2269) ) has shared an update. WuXi Biologics (Cayman) Inc. has scheduled a board...

3M ago

WuXi Biologics Wins Full Shareholder Backing at 2026 AGM

Wuxi Biologics (Cayman) ( ($HK:2269) ) has provided an update. WuXi Biologics said shareholders approved all resolutions at...

5M ago

Wuxi Biologics Grants Time-Based Restricted Shares to 21 Employees

Wuxi Biologics (Cayman) ( ($HK:2269) ) has issued an update. Wuxi Biologics has approved the grant of 288,441...

5M ago

WuXi Biologics Schedules 2026 Business Update Calls for Investors

Wuxi Biologics (Cayman) ( ($HK:2269) ) just unveiled an update. WuXi Biologics has announced that it will host...

5M ago

WuXi Biologics Launches US$400 Million Share Buyback Plan

Wuxi Biologics (Cayman) ( ($HK:2269) ) just unveiled an update. WuXi Biologics has resolved to activate its shareholder-approved...

5M ago

WuXi Biologics Sets 2026 AGM to Vote on Board, Auditors and New Share Mandate

The latest update is out from Wuxi Biologics (Cayman) ( ($HK:2269) ). WuXi Biologics (Cayman) Inc. has called...

5M ago

WuXi Biologics: Robust Backlog, High-Margin Growth Drivers, and Capacity Expansion Underpin Buy Rating

CMB International Securities analyst Jill Wu maintained a Buy rating on Wuxi Biologics (Cayman) today and set a...

7M ago

WuXi Biologics downgraded to Neutral from Buy at Goldman Sachs

Goldman Sachs downgraded WuXi Biologics to Neutral from Buy with a price target of HK$21.60, down from HK$50....

3y ago

2269 FAQ

What was Wuxi Biologics (Cayman) Inc.’s price range in the past 12 months?

Wuxi Biologics (Cayman) Inc. lowest stock price was HK$28.48 and its highest was HK$58.00 in the past 12 months.

What is Wuxi Biologics (Cayman) Inc.’s market cap?

Wuxi Biologics (Cayman) Inc.’s market cap is HK$206.04B.

When is Wuxi Biologics (Cayman) Inc.’s upcoming earnings report date?

Wuxi Biologics (Cayman) Inc.’s upcoming earnings report date is Mar 23, 2027 which is in 151 days.

How were Wuxi Biologics (Cayman) Inc.’s earnings last quarter?

Wuxi Biologics (Cayman) Inc. released its earnings results on Aug 25, 2026. The company reported HK$0.68 earnings per share for the quarter, beating the consensus estimate of HK$0.528 by HK$0.152.

Is Wuxi Biologics (Cayman) Inc. overvalued?

According to Wall Street analysts Wuxi Biologics (Cayman) Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Wuxi Biologics (Cayman) Inc. pay dividends?

Wuxi Biologics (Cayman) Inc. does not currently pay dividends.

What is Wuxi Biologics (Cayman) Inc.’s EPS estimate?

Wuxi Biologics (Cayman) Inc.’s EPS estimate is 0.85.

How many shares outstanding does Wuxi Biologics (Cayman) Inc. have?

Wuxi Biologics (Cayman) Inc. has 4,116,762,000 shares outstanding.

What happened to Wuxi Biologics (Cayman) Inc.’s price movement after its last earnings report?

Wuxi Biologics (Cayman) Inc. reported an EPS of HK$0.68 in its last earnings report, beating expectations of HK$0.528. Following the earnings report the stock price went up 7.407%.

Which hedge fund is a major shareholder of Wuxi Biologics (Cayman) Inc.?

Currently, no hedge funds are holding shares in HK:2269

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Wuxi Biologics (Cayman) Stock Smart Score

Outperform

Analyst Consensus

Strong Buy

Average Price Target:
HK$58.92 (16.33% Upside)

Technicals

Fundamentals

Return on Equity

10.51%

Trailing 12-Months

Asset Growth

14.21%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Wuxi Biologics (Cayman) Inc.

Headquartered in Wuxi, China, and established in 2014, WuXi Biologics (Cayman) Inc. delivers a comprehensive, integrated suite of services spanning the entire biologics lifecycle, from initial discovery through development to large-scale manufacturing. The company's operations have a global footprint, serving clients across the People's Republic of China, North America, Europe, and other international regions. Its diversified offerings also include specialized consultation in biopharmaceutical technology, international sales contracting, the development and deployment of advanced testing methodologies, and robust marketing and sales support. Furthermore, WuXi Biologics is involved in providing dedicated biologics clinical and manufacturing services, the production and distribution of various medical products, contract development and manufacturing (CDMO) for vaccines and associated businesses, and acting as a supplier of key materials. The firm maintains strategic partnerships with notable entities such as ImmuneOncia Therapeutics, Legochem Biosciences Inc., Worg Pharma, OncoC4, and Exelixis Inc.

Wuxi Biologics (Cayman) (2269) Earnings & Revenues

Historic Earnings Reports

2269 Company Deck

2269 Earnings Call

Q2 2026

0:00 / 0:00

2269 Stock 12 Month Forecast

Average Price Target

HK$58.92

▲(16.33% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"30":"HK$30","39":"HK$39","48":"HK$48","57":"HK$57","66":"HK$66"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":65.7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$65.70</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":58.92,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$58.92</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":47,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$47.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[30,39,48,57,66],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,56.05,56.79230769230769,57.534615384615385,58.276923076923076,59.01923076923077,59.761538461538464,60.503846153846155,61.246153846153845,61.988461538461536,62.73076923076923,63.473076923076924,64.21538461538462,64.95769230769231,{"y":65.7,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,56.05,56.270769230769226,56.49153846153846,56.71230769230769,56.933076923076925,57.15384615384615,57.37461538461538,57.59538461538462,57.816153846153846,58.036923076923074,58.25769230769231,58.47846153846154,58.69923076923077,{"y":58.92,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,56.05,55.35384615384615,54.65769230769231,53.96153846153846,53.26538461538461,52.56923076923077,51.87307692307692,51.176923076923075,50.480769230769226,49.784615384615385,49.08846153846154,48.392307692307696,47.69615384615385,{"y":47,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":40.98,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.2,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.72,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.44,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.86,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.74,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.86,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.04,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.62,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.6,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.74,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.48,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.05,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >